ClinicalTrials.gg

TargetBeta

FLT4

fms related receptor tyrosine kinase 4 · also VEGFR3, PCL, VEGFR-3 · I-set domain containing

6 programs in company-led studies act on FLT4, from 6 companies: 3 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
lenvatinibruleEisaiphase 4815 runningFLT1, KDRChEMBL
regorafenibruleBayerphase 4404 runningABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEKChEMBL
nintedanibruleBoehringer Ingelheimphase 4761 runningFGFR1, FGFR2, FGFR3, FGFR4, FLT1, KDR, PDGFRA, PDGFRBChEMBL
anlotinibruleSino Biopharmaceuticalphase 3407 runningKDR, KIT, PDGFRBChEMBL
AxitinibrulePfizerphase 3454 runningFLT1, KDRChEMBL
chiauranibruleChipscreen Biosciencesphase 3154 runningAURKB, FLT1, KDRChEMBL

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.